All In Biotech

Drug Trial Radar · NCT00103402

Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome

A Randomized Clinical Trial to Evaluate the Efficacy and Safety of 10mg Alfuzosin in the Treatment of Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) in Recently-Diagnosed and/or Newly-Symptomatic Alpha-blocker Naïve Patients

Last checked: Nov 20, 2026Latest source record: Jun 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 272 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

272

Actual

Start

Feb 2005

Primary completion

Jan 2008

Study completion Jan 2008

Sponsor

Sponsor type
NIH
Collaborators
University of Pennsylvania
First posted
Feb 8, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this randomized clinical trial is to evaluate the efficacy and safety of the alpha adrenergic blocker Alfuzosin (Uroxatral) in men with relatively new onset of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Alfuzosin is a once daily (10 mg capsule), FDA approved medication for an indication in benign prostatic hyperplasia (BPH). The effectiveness of alfuzosin in improving lower urinary tract symptoms in patients with BPH has been documented in a number of placebo-controlled studies. A number of small studies have also suggested that alfuzosin ameliorates CP/CPPS symptoms through a similar alpha-blockade mechanism. This study will enable further testing of this hypothesis

Conditions

  • Prostatitis

Interventions

  • AlfuzosinDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Decline in Total Score ≥4 for the NIH-CPSI Total Score From Baseline to 12 WeeksTime frame: Baseline and 12 weeks

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • David Geffen School of Medicine at UCLA

    Los Angeles, California

  • Stanford University Medical Center

    Stanford, California

  • Northwestern U. Feinberg School of Medicine

    Chicago, Illinois

  • University of Maryland

    Baltimore, Maryland

  • Harvard Medical School- Massachusetts General Hospital

    Boston, Massachusetts

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Cleveland Clinic

    Cleveland, Ohio

  • Temple University

    Philadelphia, Pennsylvania

  • University of Washington- Harborview Medical Center

    Seattle, Washington

  • Queen's University

    Kingston, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.